The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years’nexperience of association studies to understand the genetic architecture ofnpancreatic cancer

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68378041%3A_____%2F23%3A00577153" target="_blank" >RIV/68378041:_____/23:00577153 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/pii/S1040842823001087?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S1040842823001087?via%3Dihub</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.critrevonc.2023.104020" target="_blank" >10.1016/j.critrevonc.2023.104020</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years’nexperience of association studies to understand the genetic architecture ofnpancreatic cancer

Popis výsledku v původním jazyce

Pancreatic cancer has an incidence that almost matches its mortality. Only a small number of risk factors and 33 susceptibility loci have been identified. so Moreover, the relative rarity of pancreatic cancer poses significant hurdles for research aimed at increasing our knowledge of the genetic mechanisms contributing to the disease. Additionally, the inability to adequately power research questions prevents small monocentric studies from being successful. Several consortia have been established to pursue a better understanding of the genetic architecture of pancreatic cancers. The Pancreatic disease research (PANDoRA) consortium is the largest in Europe. PANDoRA is spread across 12 European countries, Brazil and Japan, bringing together 29 basic and clinical research groups. In the last ten years, PANDoRA has contributed to the discovery of 25 susceptibility loci, a feat that will be instrumental in stratifying the population by risk and optimizing preventive strategies.

Název v anglickém jazyce

The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years’nexperience of association studies to understand the genetic architecture ofnpancreatic cancer

Popis výsledku anglicky

Pancreatic cancer has an incidence that almost matches its mortality. Only a small number of risk factors and 33 susceptibility loci have been identified. so Moreover, the relative rarity of pancreatic cancer poses significant hurdles for research aimed at increasing our knowledge of the genetic mechanisms contributing to the disease. Additionally, the inability to adequately power research questions prevents small monocentric studies from being successful. Several consortia have been established to pursue a better understanding of the genetic architecture of pancreatic cancers. The Pancreatic disease research (PANDoRA) consortium is the largest in Europe. PANDoRA is spread across 12 European countries, Brazil and Japan, bringing together 29 basic and clinical research groups. In the last ten years, PANDoRA has contributed to the discovery of 25 susceptibility loci, a feat that will be instrumental in stratifying the population by risk and optimizing preventive strategies.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30103 - Neurosciences (including psychophysiology)

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Critical Reviews in Oncology Hematology

ISSN

1040-8428

e-ISSN

1879-0461

Svazek periodika

186

Číslo periodika v rámci svazku

jun.

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

13

Strana od-do

104020

Kód UT WoS článku

001045487200001

EID výsledku v databázi Scopus

2-s2.0-85159706732